Jinxin Fertility Group Ltd. (KYG5140J1013)

Overview

Jinxin Fertility Group Limited stands as an eminent investment holding company focused on the provision of assisted reproductive services (ARS) across China and the United States. With its pillars rooted deep in the rich history since its establishment in 1951, the company has flourished under the expertise and dedication woven into its foundation. Headquartered in Chengdu, China, Jinxin Fertility Group Limited has evolved into a beacon of hope for countless individuals and couples embarking on the journey to parenthood. Through its comprehensive suite of services and treatments, the company not only facilitates but nurtures the dream of family expansion with cutting-edge reproductive technologies, ancillary health, and support services.

Products and Services

• Assisted Reproductive Services (ARS)

  At the core of Jinxin Fertility Group Limited's offerings are its ARS, including a spectrum of treatments like artificial insemination using husband's or donor sperm and advanced in vitro fertilization (IVF) techniques. The IVF services encompass conventional IVF and embryo transfer, along with the specialized technique of intracytoplasmic sperm injection (ICSI) to address more complex fertility challenges. Catering to diverse needs and situations, these services underscore the company's commitment to bridging the gap towards parenthood.

• Support Services

  Understanding the intricacies of the fertility journey, Jinxin offers an integrative support system that includes nutrition guidance, Chinese medicine treatments, and psychological counseling. These services aim to enhance the effectiveness of ARS and provide a holistic approach to the individual's or couple's journey, recognizing the interplay between physical health, emotional well-being, and successful fertility treatments.

• Ancillary Medical Services

  Expanding its horizon beyond ARS, Jinxin Fertility Group offers a comprehensive range of ancillary medical services encompassing obstetrics, gynecology, urology, internal medicine, pediatrics, and ambulatory surgery center facilities. Whether it's routine medical care or specialized treatments, the company strives to meet the broader health needs of its clients at various life stages.

• Pre-implantation Genetic Screening (PGS)

  In its pursuit of excellence in fertility treatments, the company provides pre-implantation genetic screening testing services. This advanced genetic testing offers potential parents the peace of mind by assessing the chromosomal normalcy of embryos before transfer, thereby increasing the probability of a healthy pregnancy and reducing the risk of genetic diseases.

• Research and Development

  Demonstrating a firm commitment to innovation, Jinxin is engaged in the research and development of various IVF-related projects. From scientific research endeavors to the commercialization of new techniques and treatments, the company remains at the forefront of advancements in the field of reproductive medicine, ensuring that its services remain cutting-edge and effective.

• Additional Ventures

  Beyond its primary services, Jinxin Fertility Group has broadened its scope into investment management, management consultancy, postpartum and rehabilitation care, property investment, and real estate development and operation activities. These ventures not only signify the company's growth strategies but also its endeavor to create a supportive ecosystem for its clients.